As winter rolls in and pollution levels spike, our lungs bear the brunt of the seasonal assault. The air we breathe, filled with invisible yet potent enemies, wreaks havoc on our health. Beyond the discomfort of coughing and sneezing, this escalating crisis has sparked a significant shift in the pharmaceutical industry. The respiratory segment is witnessing unprecedented growth, a trend that reflects both a public health challenge and an industry opportunity. Let’s dive into how air pollution is fuelling this transformation and what it means for our collective future. Air Pollution: The Catalyst for Change It’s no secret that poor air quality has become a persistent menace. Post Diwali smog and chilly winter air combine to create a perfect storm, aggravating respiratory conditions across demographics. From children with wheezing and breathlessness to elderly patients grappling with asthma and chronic obstructive pulmonary disease (COPD), the impact is widespread and relentless. Even
Founded in 2015 by Manish Poddar, Rare Rabbit capitalized on the Radhamani Group’s expertise in luxury garment production, offering European-style menswear with a focus on quality and affordability. With a clear vision for urban, style-conscious consumers, Rare Rabbit quickly established itself as a premium lifestyle brand in India’s competitive fashion industry. Omnichannel Strategy and Brand Differentiation: Rare Rabbit adopted an omnichannel approach, establishing a presence in both physical stores and online platforms to maximize reach. Known for its European-inspired designs and minimalistic branding, Rare Rabbit carved out a unique space in the Indian market, attracting millennials and Gen Z shoppers with a taste for contemporary, upscale fashion. Product Expansion and Vertical Integration: Initially focused on menswear, Rare Rabbit diversified into accessories, footwear, and womenswear, expanding its appeal and customer base. Vertical integration through the Radhamani Group enab